Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Clinical profiles of 28 patients with LEC of the salivary gland
Characteristics No. of Patients/Values
Sex 
    Female 11 (39.3%)
    Male 17 (60.7%)
Age (mean) (yr) 12∼60 (39.3)
    <20 4 (14.3%)
    ≥20 ∼ <30 4 (14.3%)
    ≥30 ∼ <40 6 (21.4%)
    ≥40 ∼ <50 4 (14.3%)
    ≥50 ∼ <60 8 (28.6%)
    ≥60 2 (7.1%)
Symptom duration (mean) (mo) 0.∼120 (25)
    <24 16 (57.1%)
    ≥24 12 (42.9%)
Epstein-Barr virus 
    Positive 27 (96.4%)
    Negative 1 (3.6%)
Clinical staging 
    I 1 (3.6%)
    II 7 (25.0%)
    III 8 (28.5%)
    IV 12 (42.9%)
Treatment 
    Surgery 7 (25%)
    Surgery and radiotherapy 18 (64.2%)
    Surgery, radiotherapy, and chemotherapy 2 (7.2%)
    Radiotherapy and chemotherapy 1 (3.6%)
Local recurrence 3 (10.7%)
Distant metastasis 4 (14.3%)

Characteristics	No. of Patients/Values
Sex
Female	11 (39.3%)
Male	17 (60.7%)
Age (mean) (yr)	12∼60 (39.3)
<20	4 (14.3%)
≥20 ∼ <30	4 (14.3%)
≥30 ∼ <40	6 (21.4%)
≥40 ∼ <50	4 (14.3%)
≥50 ∼ <60	8 (28.6%)
≥60	2 (7.1%)
Symptom duration (mean) (mo)	0.∼120 (25)
<24	16 (57.1%)
≥24	12 (42.9%)
Epstein-Barr virus
Positive	27 (96.4%)
Negative	1 (3.6%)
Clinical staging
I	1 (3.6%)
II	7 (25.0%)
III	8 (28.5%)
IV	12 (42.9%)
Treatment
Surgery	7 (25%)
Surgery and radiotherapy	18 (64.2%)
Surgery, radiotherapy, and chemotherapy	2 (7.2%)
Radiotherapy and chemotherapy	1 (3.6%)
Local recurrence	3 (10.7%)
Distant metastasis	4 (14.3%)